Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 17, 2025

Alexa Fluor(R) 647 anti-mouse CD4

RRID:AB_389325 Type: Antibody

Proper Citation

(BioLegend Cat# 100530, RRID:AB_389325)

Antibody Information

URL: http://antibodyregistry.org/AB_389325

Proper Citation: (BioLegend Cat# 100530, RRID:AB_389325)

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, 3D IHC, IHC-F

Antibody Name: Alexa Fluor(R) 647 anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone RM4-5

Antibody ID: AB_389325

Vendor: BioLegend

Catalog Number: 100530

Alternative Catalog Numbers: 100533

Record Creation Time: 20231110T044640+0000

Record Last Update: 20241115T094021+0000

Ratings and Alerts

No rating or validation information has been found for Alexa Fluor(R) 647 anti-mouse CD4.

No alerts have been found for Alexa Fluor(R) 647 anti-mouse CD4.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

West EE, et al. (2023) Loss of CD4+ T cell-intrinsic arginase 1 accelerates Th1 response kinetics and reduces lung pathology during influenza infection. Immunity, 56(9), 2036.

Ozga AJ, et al. (2022) CXCL10 chemokine regulates heterogeneity of the CD8+ T cell response and viral set point during chronic infection. Immunity, 55(1), 82.

Cautivo KM, et al. (2022) Interferon gamma constrains type 2 lymphocyte niche boundaries during mixed inflammation. Immunity, 55(2), 254.

Hua Y, et al. (2022) Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. Cancer cell, 40(12), 1600.

Chryplewicz A, et al. (2022) Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity. Cancer cell, 40(10), 1111.

El-Naccache DW, et al. (2022) Adenosine metabolized from extracellular ATP promotes type 2 immunity through triggering A2BAR signaling in intestinal epithelial cells. Cell reports, 40(5), 111150.

Okano M, et al. (2022) Interleukin-33-activated neuropeptide CGRP-producing memory Th2 cells cooperate with somatosensory neurons to induce conjunctival itch. Immunity, 55(12), 2352.

Chaurasiya S, et al. (2021) Toward comprehensive imaging of oncolytic viroimmunotherapy. Molecular therapy oncolytics, 23, 303.

Freed-Pastor WA, et al. (2021) The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer cell, 39(10), 1342.

Zhou JY, et al. (2021) Integration of IL-2 and IL-4 signals coordinates divergent regulatory T

cell responses and drives therapeutic efficacy. eLife, 10.

Dikiy S, et al. (2021) A distal Foxp3 enhancer enables interleukin-2 dependent thymic Treg cell lineage commitment for robust immune tolerance. Immunity, 54(5), 931.

Kim SI, et al. (2021) Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity. Molecular cancer therapeutics, 20(1), 173.

Jamali A, et al. (2020) Characterization of Resident Corneal Plasmacytoid Dendritic Cells and Their Pivotal Role in Herpes Simplex Keratitis. Cell reports, 32(9), 108099.

Sinclair LV, et al. (2019) Antigen receptor control of methionine metabolism in T cells. eLife, 8.

Beloor J, et al. (2018) Small Interfering RNA-Mediated Control of Virus Replication in the CNS Is Therapeutic and Enables Natural Immunity to West Nile Virus. Cell host & microbe, 23(4), 549.